AU2001229501A1 - Antisense modulation of inducible nitric oxide synthase expression - Google Patents
Antisense modulation of inducible nitric oxide synthase expressionInfo
- Publication number
- AU2001229501A1 AU2001229501A1 AU2001229501A AU2950101A AU2001229501A1 AU 2001229501 A1 AU2001229501 A1 AU 2001229501A1 AU 2001229501 A AU2001229501 A AU 2001229501A AU 2950101 A AU2950101 A AU 2950101A AU 2001229501 A1 AU2001229501 A1 AU 2001229501A1
- Authority
- AU
- Australia
- Prior art keywords
- nitric oxide
- oxide synthase
- inducible nitric
- synthase expression
- antisense modulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
- C12Y114/13039—Nitric-oxide synthase (NADPH dependent) (1.14.13.39)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49020800A | 2000-01-24 | 2000-01-24 | |
US09490208 | 2000-01-24 | ||
PCT/US2001/001381 WO2001052902A1 (en) | 2000-01-24 | 2001-01-15 | Antisense modulation of inducible nitric oxide synthase expression |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001229501A1 true AU2001229501A1 (en) | 2001-07-31 |
Family
ID=23947053
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001229501A Abandoned AU2001229501A1 (en) | 2000-01-24 | 2001-01-15 | Antisense modulation of inducible nitric oxide synthase expression |
Country Status (5)
Country | Link |
---|---|
US (1) | US20050113322A1 (en) |
EP (1) | EP1250157A4 (en) |
JP (1) | JP2003520042A (en) |
AU (1) | AU2001229501A1 (en) |
WO (1) | WO2001052902A1 (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
US7888324B2 (en) | 2001-08-01 | 2011-02-15 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
US7511131B2 (en) | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
US20050287558A1 (en) | 2004-05-05 | 2005-12-29 | Crooke Rosanne M | SNPs of apolipoprotein B and modulation of their expression |
AU2007253909B2 (en) | 2006-05-05 | 2012-08-09 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of GCCR |
CA2667547C (en) | 2006-10-27 | 2014-07-29 | Boehringer Ingelheim International Gmbh | Piperidyl-propane-thiol ccr3 modulators |
WO2008118883A1 (en) | 2007-03-24 | 2008-10-02 | Isis Pharmaceuticals, Inc. | Administering antisense oligonucleotides complementary to human apolipoprotein b |
UA99309C2 (en) | 2007-10-19 | 2012-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Substituted piperidino-dihydrothienopyrimidines |
KR101646948B1 (en) * | 2008-09-30 | 2016-08-09 | 후지필름 가부시키가이샤 | Ceramide dispersion and method for producing same |
EP2816040B1 (en) | 2008-12-19 | 2018-10-17 | Centrexion Therapeutics Corporation | Process for the production of CCR2 receptor antagonists and intermediates thereof |
US9107933B2 (en) | 2009-03-16 | 2015-08-18 | Isis Pharmaceuticals, Inc. | Compositions and methods of targeting apolipoprotein B for the reduction of apolipoprotein C-III |
AU2011209274B8 (en) | 2010-01-29 | 2015-08-13 | Boehringer Ingelheim International Gmbh | Substituted naphthyridines and their use as Syk kinase inhibitors |
JP5959537B2 (en) | 2011-01-28 | 2016-08-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Substituted pyridinyl-pyrimidines and their use as pharmaceuticals |
EP2614848B1 (en) | 2012-01-13 | 2020-07-01 | Boehringer Ingelheim International GmbH | Inhaler and capsule for an inhaler |
JP6037315B2 (en) | 2011-05-27 | 2016-12-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Inhaler and capsule for inhaler |
JP5860960B2 (en) | 2011-07-26 | 2016-02-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Substituted quinolines and their use as pharmaceuticals |
US20130059866A1 (en) | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
WO2013064450A1 (en) | 2011-11-02 | 2013-05-10 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof |
US8859559B2 (en) | 2011-12-20 | 2014-10-14 | Boehringer Ingelheim International Gmbh | Substituted pyrazines and their use in the treatment of disease |
US9096579B2 (en) | 2012-04-20 | 2015-08-04 | Boehringer Ingelheim International Gmbh | Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments |
WO2013174757A1 (en) | 2012-05-25 | 2013-11-28 | Boehringer Ingelheim International Gmbh | Tertiary amines, medicaments containing said amines, use thereof and processes for the preparation thereof |
JP6072920B2 (en) | 2012-09-24 | 2017-02-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Heterocyclic compounds, drugs containing said compounds, their use and methods for their preparation |
ME03472B (en) | 2014-03-19 | 2020-01-20 | Boehringer Ingelheim Int | Heteroaryl sik inhibitors |
SG10201913575VA (en) | 2014-04-15 | 2020-02-27 | Vertex Pharma | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
JP6896619B2 (en) | 2014-10-06 | 2021-06-30 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Cystic fibrosis transmembrane conductance regulator modulator |
US11931325B2 (en) * | 2015-10-20 | 2024-03-19 | Eaderm Co., Ltd. | Hair-growth promoting composition and usage thereof |
US11642365B2 (en) * | 2017-09-22 | 2023-05-09 | John Mansell | Compositions and methods for treatment of sepsis-related disorders |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5028627A (en) * | 1989-09-13 | 1991-07-02 | Cornell Research Foundation, Inc. | Method of using arginine derivatives to inhibit systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor |
US5216025A (en) * | 1989-09-13 | 1993-06-01 | Board Of Regents, The University Of Texas System | Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients |
US5766909A (en) * | 1992-02-04 | 1998-06-16 | Merck & Co., Inc. | DNA encoding inducible nitric oxide synthase |
US5872242A (en) * | 1992-10-05 | 1999-02-16 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of ras |
GB9306386D0 (en) * | 1993-03-26 | 1993-05-19 | Wellcome Found | Gene expression |
US5695761A (en) * | 1993-12-23 | 1997-12-09 | Rutgers University | Suppression of nitric oxide production by osteopontin |
US5850004A (en) * | 1994-08-02 | 1998-12-15 | Cornell Research Foundation, Inc. | Transgenic mouse deficient in inducible nitric oxide synthase |
US5789395A (en) * | 1996-08-30 | 1998-08-04 | The Research Foundation Of State University Of New York | Method of using tetracycline compounds for inhibition of endogenous nitric oxide production |
WO2000066725A1 (en) * | 1999-05-04 | 2000-11-09 | Aventis Pharma S.A. | Use of inducible no-synthase antisense oligonucleotides for preventing and treating cerebral ischemia |
-
2001
- 2001-01-15 WO PCT/US2001/001381 patent/WO2001052902A1/en not_active Application Discontinuation
- 2001-01-15 JP JP2001552949A patent/JP2003520042A/en active Pending
- 2001-01-15 AU AU2001229501A patent/AU2001229501A1/en not_active Abandoned
- 2001-01-16 US US10/182,049 patent/US20050113322A1/en not_active Abandoned
- 2001-01-16 EP EP01942564A patent/EP1250157A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1250157A4 (en) | 2004-12-29 |
WO2001052902A1 (en) | 2001-07-26 |
US20050113322A1 (en) | 2005-05-26 |
JP2003520042A (en) | 2003-07-02 |
EP1250157A1 (en) | 2002-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001229501A1 (en) | Antisense modulation of inducible nitric oxide synthase expression | |
AU2001294926A1 (en) | Antisense modulation of smad6 expression | |
AU2001289085A1 (en) | Antisense modulation of flip-c expression | |
AU4430599A (en) | Inhibitors of nitric oxide synthase | |
AU2002309819A1 (en) | Antisense modulation of PTP1B expression | |
AU2001229447A1 (en) | Antisense modulation of smad7 expression | |
MXPA03000772A (en) | Hexahydro-7-1h-azepin-2-yl-haxanoic acid derivatives as inhibitors of inducible nitric oxide synthase. | |
AU2001277054A1 (en) | Antisense modulation of lysophospholipase i expression | |
AU2001278077A1 (en) | Antisense modulation of ptp1b expression | |
AU2001261808A1 (en) | Antisense modulation of pten expression | |
AU2001263171A1 (en) | Antisense modulation of tert expression | |
AU2001227847A1 (en) | Antisense modulation of pepck-cytosolic expression | |
AU2298301A (en) | Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators | |
AU2002366788A1 (en) | Antisense modulation of ship-1 expression | |
AU2001257220A1 (en) | Antisense modulation of inhibitor of dna binding-1 expression | |
AU2002318139A1 (en) | Antisense modulation of src-c expression | |
AU2001280591A1 (en) | Modulation of nitric oxide synthase by pkc | |
AU2002226064A1 (en) | Antisense modulation of talin expression | |
AU2002357102A1 (en) | Antisense modulation of cd36l1 expression | |
AU2001282746A1 (en) | Novel phenylheteroazetidines, useful as nitric oxide synthase inhibitors | |
AU2001287136A1 (en) | Antisense modulation of glioma-associated oncogene-1 expression | |
AU2001234462A1 (en) | Antisense modulation of cot oncogene expression | |
AU2001296412A1 (en) | Antisense modulation of mekk4 expression | |
GB9810299D0 (en) | Use of nitric oxide synthase inhibitors | |
AU2001234461A1 (en) | Antisense modulation of daxx expression |